A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK 9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects-Reference-Cited by-同舟云学术

A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK 9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects

Published:2014-11-24 Issue:6 Volume:32 Page:297-301
ISSN:1755-5914
Container-title:Cardiovascular Therapeutics
language:en
Short-container-title:Cardiovasc Ther

Author:

Lunven Catherine¹,Paehler Tobias²,Poitiers Franck¹,Brunet Aurélie³,Rey Jacques¹,Hanotin Corinne¹,Sasiela William J.⁴

Affiliation:

1. Sanofi Paris France

2. Sanofi Frankfurt Germany

3. Sanofi Montpellier France

4. Regeneron Pharmaceuticals, Inc. Tarrytown NY USA

Funder

Regeneron

Publisher

Wiley

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1755-5922.12093

Reference10 articles.

1. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

2. Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

3. Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

4. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

5. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15;Journal of Atherosclerosis and Thrombosis;2024-06-01

2. Role of PCSK9 inhibitors in the management of dyslipidaemia;Indian Heart Journal;2024-03

3. Genetics, Safety, Cost-Effectiveness, and Accessibility of Injectable Lipid-Lowering Agents: A Narrative Review;Journal of Lipids;2023-03-08

4. Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9;Pharmacological Research;2022-10

5. Combined Semi-mechanistic Target-Mediated Drug Disposition and Pharmacokinetic–Pharmacodynamic Models of Alirocumab, PCSK9, and Low-Density Lipoprotein Cholesterol in a Pooled Analysis of Randomized Phase I/II/III Studies;European Journal of Drug Metabolism and Pharmacokinetics;2022-08-16